FindTrial
Sign In

The strategy of treatment of moderate ischemic mitral regurgitation and the predictors of change of mitral regurgitation

The strategy of treatment of moderate ischemic mitral regurgitation and the predictors of change of mitral regurgitation

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-INR-17011319
Enrollment
Unknown
Registered
2017-05-07
Start date
2017-08-01
Completion date
Unknown
Last updated
2017-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Disease

Interventions

CABG Group:Coronary artery bypass grafting (CABG)
CABG+MVR Group:Coronary artery bypass grafting (CABG) + mitral valve repair

Sponsors

Huashan Hospital of Fudan University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Coronary artery disease patients diagnosed by coronary angiogram with a corresponding regional wall motion abnormality by echocardiography; 2) structually normal heart valves; 3) sinus rhythm; 4) high echocardiography image quality allowing 3D quantitative analysis; 5) stable clincial condition allowing surgery.

Exclusion criteria

Exclusion criteria: 1) structually mitral valve disease; 2) other valve diseasesp; 3) atrial fibrillation; 4) unstable clinical condition; 5) images not appropriate for 3D echocardiography analysis.

Design outcomes

Primary

MeasureTime frame
Survival;Clinical complications;degree of mitral regurgitation;mitral valve structure;LV structure and function;LV dyssynchrony;—

Secondary

MeasureTime frame
preoperative risk predictors;—

Countries

China

Contacts

Public ContactYiqing Wang

Huashan Hospital of Fudan University

wangyiqing@huashan.org.cn+86 13801782460

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026